Company profile: Achieve Life Sciences
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical products, manufacturing and developing cytisinicline, a plant-based alkaloid for nicotine addiction, including smoking and e-cigarette cessation, that interacts with nicotine receptors to reduce withdrawal symptoms and the reward associated with nicotine products.
Products and services
- Cytisine Development: The firm engineers a specialty-focused program developing cytisine as a smoking cessation aid, targeting tobacco users by advancing its application for helping quit smoking
- Cytisinicline: A plant-based alkaloid therapy engineered for nicotine addiction, including smoking and e‑cigarette cessation, interacting with brain nicotine receptors to reduce withdrawal symptoms and nicotine-product reward
- Pharmaceutical Products Manufacturing: The company produces specialty pharmaceutical products as a privately-held operation, fabricating medicines to underpin its role as a specialty pharmaceutical provider
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Achieve Life Sciences
Wallaby Medical
HQ: United States
Website
- Description: Provider of the Avenir coil system and medical devices for stroke treatment, operating as a manufacturing company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wallaby Medical company profile →
T3D Therapeutics
HQ: United States
Website
- Description: Provider of remedial therapeutics for Alzheimer's disease and other CNS disorders, including T3D-959, an investigational oral drug candidate designed to treat Alzheimer's by improving brain glucose and lipid metabolism, potentially addressing multiple disease manifestations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3D Therapeutics company profile →
Axsome Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for neurological disorders, including Auvelity for major depressive disorder and Sunosi to improve wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea or narcolepsy; developing AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-07 for acute migraine, and AXS-12 for narcolepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axsome Therapeutics company profile →
Magnus Medical
HQ: United States
Website
- Description: Provider of closed-loop neuromodulation technology for intractable neurological and psychiatric disorders. Offers the SAINT Neuromodulation System, a non-invasive magnetic stimulation treatment targeting brain areas associated with depression and delivered over five days, and the Open Label Optimization (OLO) clinical research program evaluating SAINT's effectiveness in Major Depressive Disorder.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Magnus Medical company profile →
Avalo Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for immunologic, immuno-oncologic and rare genetic disorders, advancing treatments for rare and orphan diseases. Pipeline includes AVTX-009 (anti-IL-1β) for inflammatory diseases; quisovalimab (anti-LIGHT) for inflammatory conditions; AVTX-008 (BTLA agonist) for immune dysregulation; and AVTX-002 (anti-LIGHT) in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avalo Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Achieve Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Achieve Life Sciences
2.2 - Growth funds investing in similar companies to Achieve Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Achieve Life Sciences
4.2 - Public trading comparable groups for Achieve Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →